Wetherby drug developer Avacta hails progress despite operating losses widening to £29.1m in 2021

Drug developer Avacta said it had a period of transformational progress despite seeing operating losses widen for the year ended December 31, 2021.

The Wetherby-based firm reported revenues of £2.9m, up from £2.1m the previous year. However, it suffered an operating loss of £29.1m, widening from a loss of £18.8m the year before.

Avacta said increased research and development and manufacturing investment within its diagnostics division and clinical development costs in the therapeutics division, led to a reported loss from continuing operations of £26.4m.

Sign up to our Business newsletter

Dr Alastair Smith, CEO of Avacta, said: "It has been a period of transformational progress for the group, including many firsts for both the therapeutics and diagnostics divisions and despite the many operational challenges resulting from the impact of the pandemic. I would like to thank all our staff for the outstanding commitment shown to deliver this progress.

Dr Alastair Smith, CEO of Avacta, said: "It has been a period of transformational progress for the group".

"Our therapeutics division has transitioned to being a clinical stage business through the dosing of the first patient in the Phase I study of AVA6000, increasing the division's intrinsic value and attractiveness to specialist investors and pharmaceutical partners.

"Success in the ongoing Phase Ia study, which will likely read-out in the middle of 2022, will not only potentially create a valuable chemotherapy asset but will also be a first validation of the pre|CISION platform, highlighting a promising pipeline of chemotherapies with the potential to significantly improve patients' lives.

"Our diagnostic division is now ISO13485 certified and has established all the necessary product development functions in-house, removing the need to rely on multiple external partners. We are now developing a pipeline of IVD products as well as improving the performance of our antigen test for Covid-19 to ensure it can be commercialised as soon as possible.

"We are confident and excited about the immediate and long-term future prospects of the Group, with both potential near-term value drivers relating to AVA6000's clinical trial progress, a pipeline of IVD products and a redeveloped SARS-CoV-2 antigen test offering immediate and long-term opportunities."

The firm said it is "very confident and excited about the immediate and long-term opportunities".


Support The Yorkshire Post and become a subscriber today.

Your subscription will help us to continue to bring quality news to the people of Yorkshire. In return, you'll see fewer ads on site, get free access to our app and receive exclusive members-only offers.

So, please - if you can - pay for our work. Just £5 per month is the starting point. If you think that which we are trying to achieve is worth more, you can pay us what you think we are worth. By doing so, you will be investing in something that is becoming increasingly rare. Independent journalism that cares less about right and left and more about right and wrong. Journalism you can trust.

Thank you

James Mitchinson